Your browser doesn't support javascript.
loading
Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
Ren, Huiyu; Bakas, Nicole A; Vamos, Mitchell; Chaikuad, Apirat; Limpert, Allison S; Wimer, Carina D; Brun, Sonja N; Lambert, Lester J; Tautz, Lutz; Celeridad, Maria; Sheffler, Douglas J; Knapp, Stefan; Shaw, Reuben J; Cosford, Nicholas D P.
  • Ren H; Cancer Molecules & Structures Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
  • Bakas NA; Cancer Molecules & Structures Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
  • Vamos M; Cancer Molecules & Structures Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
  • Chaikuad A; Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe-University Frankfurt, Frankfurt 60438, Germany.
  • Limpert AS; Institute of Pharmaceutical Chemistry, Goethe-University Frankfurt, Frankfurt 60438, Germany.
  • Wimer CD; Cancer Molecules & Structures Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
  • Brun SN; Cancer Molecules & Structures Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
  • Lambert LJ; Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, San Diego, California 92037, United States.
  • Tautz L; Cancer Molecules & Structures Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
  • Celeridad M; Cancer Molecules & Structures Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
  • Sheffler DJ; Cancer Molecules & Structures Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
  • Knapp S; Cancer Molecules & Structures Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
  • Shaw RJ; Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe-University Frankfurt, Frankfurt 60438, Germany.
  • Cosford NDP; Institute of Pharmaceutical Chemistry, Goethe-University Frankfurt, Frankfurt 60438, Germany.
J Med Chem ; 63(23): 14609-14625, 2020 12 10.
Article en En | MEDLINE | ID: mdl-33200929
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ftalazinas / Piperazinas / Pirimidinas / Autofagia / Péptidos y Proteínas de Señalización Intracelular / Inhibidores de Proteínas Quinasas / Homólogo de la Proteína 1 Relacionada con la Autofagia / Antineoplásicos Límite: Animals / Female / Humans Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ftalazinas / Piperazinas / Pirimidinas / Autofagia / Péptidos y Proteínas de Señalización Intracelular / Inhibidores de Proteínas Quinasas / Homólogo de la Proteína 1 Relacionada con la Autofagia / Antineoplásicos Límite: Animals / Female / Humans Idioma: En Año: 2020 Tipo del documento: Article